- Home
- FLYE vs BRTX Comparison
FLYE vs BRTX Comparison
Compare FLYE & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYE
- BRTX
- Stock Information
- Founded
- FLYE 2018
- BRTX 1997
- Country
- FLYE United States
- BRTX United States
- Employees
- FLYE N/A
- BRTX N/A
- Industry
- FLYE Aerospace
- BRTX Managed Health Care
- Sector
- FLYE Industrials
- BRTX Health Care
- Exchange
- FLYE Nasdaq
- BRTX Nasdaq
- Market Cap
- FLYE 8.5M
- BRTX 9.7M
- IPO Year
- FLYE 2024
- BRTX N/A
- Fundamental
- Price
- FLYE $4.06
- BRTX $1.01
- Analyst Decision
- FLYE
- BRTX
- Analyst Count
- FLYE 0
- BRTX 0
- Target Price
- FLYE N/A
- BRTX N/A
- AVG Volume (30 Days)
- FLYE 55.2K
- BRTX 98.9K
- Earning Date
- FLYE 11-19-2025
- BRTX 11-12-2025
- Dividend Yield
- FLYE N/A
- BRTX N/A
- EPS Growth
- FLYE N/A
- BRTX N/A
- EPS
- FLYE N/A
- BRTX N/A
- Revenue
- FLYE $22,881,935.00
- BRTX $383,400.00
- Revenue This Year
- FLYE N/A
- BRTX $232.67
- Revenue Next Year
- FLYE N/A
- BRTX $52.92
- P/E Ratio
- FLYE N/A
- BRTX N/A
- Revenue Growth
- FLYE N/A
- BRTX 1.70
- 52 Week Low
- FLYE $3.83
- BRTX $1.00
- 52 Week High
- FLYE $166.00
- BRTX $2.55
- Technical
- Relative Strength Index (RSI)
- FLYE 56.83
- BRTX 29.13
- Support Level
- FLYE $5.37
- BRTX $1.00
- Resistance Level
- FLYE $4.21
- BRTX $1.45
- Average True Range (ATR)
- FLYE 0.34
- BRTX 0.12
- MACD
- FLYE -0.20
- BRTX -0.03
- Stochastic Oscillator
- FLYE 10.09
- BRTX 8.60
About FLYE Fly-E Group Inc. Common Stock
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.